







In spite of its essential role as the
carrier of genetic information, DNA is
not an inert structure. The genome is
susceptible to potentially mutagenic
threats of both endogenous and
environmental origin. A dramatic
threat to the covalent structure of
DNA is posed by breaks in the
phosphate backbone affecting one or
both strands of the Watson–Crick
double helix. Ionizing radiation and
certain chemotherapeutic drugs, for
example, generate single-strand and,
less commonly, double-strand breaks,
as well as clustered base lesions in
both DNA strands where
simultaneous excision-repair has the
potential to convert a single-strand to
a double-strand break. The cell is not
unduly troubled by single-strand
breaks, as it sees these as reaction
intermediates during the excision-
repair of DNA base damage, and so
deals with them accordingly.
However, a double-strand break is an
extremely dangerous lesion, posing
one of the greatest threats not just to
the informational integrity but also to
the structural cohesion of the DNA.
Unless quickly repaired, such breaks
can lead to chromosomal deletion,
loss, rearrangement or cytotoxicity if
the cell continues its cycle of DNA
replication and cell division. Not
surprisingly, numerous proteins are
involved in detecting and repairing
DNA double-strand breaks, or
checking cell-cycle progression until
repair is complete. 
Double-strand break repair
mechanisms rely on enzymes which
evolved primarily to deal with
developmentally programmed
double-strand breaks. The deliberate
targeted introduction of DNA double-
strand breaks by endonucleases and
their coordinated repair underpin key
biological processes such as
recombination between homologous
chromosomes during meiosis or V(D)J
rearrangements of immunoglobulin
and T-cell receptor genes. The two
main repair mechanisms that the cell
can use when faced with an
accidentally introduced DNA double-
strand break, homologous
recombination and non-homologous
end joining, largely recruit those
enzymes involved ordinarily in
meiotic and V(D)J recombination,
respectively.
The strategy of homologous
recombination relies on the fact that
replication generates an identical
copy of the cellular DNA and the
undamaged copy can be used as a
template for resynthesis and repair of
a damaged DNA strand. In this mode,
homologous recombination is
restricted to the S phase of the cell
cycle, and serves to restart the
replication machinery by resolving
unfavourable DNA structures
generated when a replication fork
stalls. Homologous recombination
requires extensive stretches of DNA
sequence homology but is then a very
accurate method of repair. By
contrast, non-homologous end joining
is a much more robust but low fidelity
form of double-strand break repair,
where the broken ends are simply
fused together again irrespective of
DNA sequence. This process requires
at most a few base pairs of homology
between the two broken ends, but
may lead to loss of nucleotides at the
join, hence the alternative names of
‘illegitimate recombination’ or ‘error-
prone recombination’. As this end
joining does not require a second
homologous DNA duplex, it is of
major importance in the G1 phase of
the cell cycle where there is only a
single copy of each chromosome.
This article will focus on non-
homologous end joining as a
mechanism of DNA repair.
Responses to a double-strand break 
Although single-strand breaks are
formed as reaction intermediates
during the excision-repair of DNA
base lesions, these are continuously
protected by the assembly of repair
enzymes at the site of a lesion. Such
protection is also likely to be
provided by the replisome to double-
strand breaks arising at a replication
fork. Similarly, double-strand breaks
introduced during meiosis may be
physically constrained by a
synaptonemal complex. In contrast,
an accidental strand break is a rather
exposed target, vulnerable to the
unwanted attention of nucleases.
A large number of nuclear proteins
specifically bind to DNA double-
strand breaks. These proteins not only
protect the lesion, but also signal the
presence of the damage to the cell so
that it can activate the appropriate
repair pathway and delay the cell
cycle until the damage has been
repaired. Alternatively, an extensively
damaged cell may execute its own
death by activating apoptosis (Figure
1). Proteins binding to DNA double-
strand breaks include the ATM —
and probably ATR — protein kinases
that signal the presence of damage to
the cell cycle machinery, the
RAD50–MRE11–p95 complex that
may be involved in processing of
DNA ends as well as damage
signalling, and the homologous
recombination protein RAD52. The
catalytic domain of DNA-dependent
protein kinase (DNA-PKcs), Ku and
the DNA ligase IV–XRCC4
heterodimer are also able to bind;
these are all components of the non-
homologous end joining pathway.
It is still unclear how the cell
chooses which pathway to use to
repair a double-strand break,
although the nature of the DNA ends
at the break, the context in terms of
cell cycle stage or nuclear
compartment, as well as the balance
between levels of the RAD52 and Ku
proteins, all apparently affect this
decision. Furthermore, the yeast
Saccharomyces cerevisiae appears to
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favour using homologous
recombination whenever possible,
whereas mammalian cells are very
efficient at non-homologous end
joining, although homologous
recombination may be more
prevalent than first thought. The
basis for this difference is unclear,
but may minimize the risk of gene
amplifications or deletions that might
otherwise result because of repetitive
sequences in the mammalian genome.
Mechanism of end joining
The first requisite for repairing a
double-strand break is to bind and
tether the DNA ends, so that they are
not only protected from further
degradation but also brought into
proximity for rejoining. Although
several components of the non-
homologous end joining pathway are
able to bind DNA, the protein
binding most avidly is Ku, a
heterodimer of related 70 and 80 kDa
subunits. In mammalian cells, Ku
forms a complex with DNA-PKcs
(‘DNA-PK’, without the subscript,
strictly refers to this complex),
recruiting it to the break, where the
complex bridges the DNA ends and
initiates assembly of the other
components of the end joining
pathway. DNA-PKcs is a very large
and rather enigmatic protein. It does
indeed, as its name suggests, have
protein kinase activity, which is
activated by binding Ku in the
presence of DNA ends, and it
phosphorylates several proteins,
including other end-joining
components and signalling proteins
such as p53. However, there are two
puzzling issues here: the kinase
function is absolutely required for end
joining but the essential target
proteins remain unidentified; and
there is no equivalent of DNA-PKcs in
yeast, yet it is not clear whether there
are fundamental differences in non-
homologous end joining between
mammalian and yeast cells.
Once the DNA ends have been
bound by Ku and DNA-PKcs, another
protein complex, DNA ligase
IV–XRCC4, is recruited and ligates
the DNA ends (Figure 2). However,
the above factors are necessary but
not sufficient for efficient end joining
in an in vitro system and efforts in
several laboratories are actively
seeking the ‘missing’ components.
These may not necessarily be other
proteins: inositol phosphate (IP6) is
bound by DNA-PK and stimulates
end joining in vitro. Furthermore,
in vivo, a double-strand break rarely
has ends that can be immediately
rejoined by a DNA ligase; rather there
could be single-strand overhangs at
the break which need to be trimmed
by an exonuclease and gaps to be
filled in by a DNA polymerase. It is
unclear which enzymes are employed
in these roles, although interaction
between the Ku70 and MRE11
proteins may implicate the latter’s
3′→5′ exonuclease activity in non-
homologous end joining.
Defective end joining
Cells with mutations in genes that
encode components of the non-
homologous end joining pathway
are hypersensitive to ionizing
radiation. Of a panel of 11 ionizing
radiation-sensitive mutant rodent cell
lines, four — IR4 to IR7 — are
deficient in end joining factors.
These lines can be complemented by
human genes XRCC4 to 7,
corresponding to XRCC4, Ku80,
Ku70 and DNA-PKcs, respectively.
(XRCC stands for X-ray cross
complementing.) Furthermore, a
mutant mouse strain shown to have
severe combined immunodeficiency,
or SCID, is also radiosensitive. These
mice harbour a mutation in the
DNA-PKcs gene so that they cannot
carry out V(D)J recombination of
their immunoglobulin and T-cell
receptor genes. This provided the
first indication of the link between
V(D)J recombination, ionizing
radiation sensitivity, and the repair of
both developmentally programmed
as well as accidental DNA double-
strand breaks by non-homologous
end joining. Subsequently, targeted
gene disruption of DNA-PKcs in the
mouse was shown to recapitulate the
SCID phenotype, as do Ku70 and
Ku80 knockout mice. Surprisingly,
deficiencies in DNA-PKcs or Ku70/80
have not been reported in human
SCID and it was thought that such
cases might be inviable. However, a
recent study of radiosensitive SCID
patients identified mutations in a
novel DNA double-strand break
repair/V(D)J recombination protein;
it will now be of great interest to
establish the previously unidentified
role of this protein in non-
homologous end joining.
Prior to this discovery, DNA
ligase IV had been unique amongst
the end joining proteins in its
relationship to human disease. A
defect in DNA ligase IV was
identified in a patient with childhood
leukaemia who died from an adverse
reaction to conventional radiotherapy,
and cells derived from the patient
were radiosensitive. Although work
from knockout mouse models has
shown that non-homologous end
joining factors act as genome
‘guardians’, protecting against genome
instability and cancer, it is not clear
how frequently end joining defects
Figure 1
Cellular responses to a DNA double-strand
break. The cell is alerted to the presence of a
DNA double-strand break by DNA damage
sensing and signalling mechanisms. The
damage is channeled into the appropriate
DNA repair pathway, the cell cycle is
arrested as necessary until repair is
complete or, depending on the cell type and
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contribute to spontaneous tumours in
the general population, nor whether
they occur in the 1 in 4,000 cancer
patients that over-respond to standard
radiotherapy. In the case of DNA
ligase IV or XRCC4, these would be
subtle point mutations in the gene as,
in contrast to DNA-PKcs and
Ku70/80, targeted disruption of DNA
ligase IV or XRCC4 surprisingly
results in embryonic lethality in mice.
These null mice show widespread
apoptosis of newly generated neurons
in the central nervous system. It
seems that neuronal cells are
particularly sensitive to undergoing
apoptosis, and blocking the apoptotic
pathway, by deletion of the p53 or
ATM genes, rescues the null mice
from both neuronal cell death and
embryonic lethality. Intriguingly, the
incidence, nature and source of DNA
damage in the developing embryonic
nervous system, that requires the
function of DNA ligase IV–XRCC4,
have yet to be resolved.
Context and future prospects
In a field where we are still
identifying the key players, it is clear
that there is much left to learn about
non-homologous end joining as a
mechanism of DNA repair. And any
process acting on DNA must be
considered in the broader context of
chromatin conformation and sub-
nuclear structure: there is clear
evidence, largely from yeast, of
interactions between non-
homologous end joining and
chromatin remodelling. Furthermore,
certain end joining factors are
essential to maintain the length of
telomeres, presenting the paradox of
end joining proteins binding to DNA
ends that must not be joined. Ku in
particular seems play a pivotal role in
several cellular processes. A recent
report of a functional interaction
between Ku70 with the BLM
protein, which is associated with
homologous recombination,
highlights an emerging interplay
between non-homologous end joining
and alternative repair pathways, as
well as the coordination of repair with
other cellular processes in the
concerted response to a DNA double-
strand break. 
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Figure 2
Repair of a DNA double-strand break by non-
homologous end joining. The DNA ends are
bound by the Ku70/80 heterodimer, which in
turn binds and activates DNA-PKcs. The
complex of Ku70/80 and DNA-PKcs protects
the ends, directs assembly of the other
factors and in some way bridges the DNA
break. Finally, the DNA ligase IV-XRCC4
heterodimer is recruited and effects repair by
ligating the DNA ends.
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